@article{ Khawaja Tahir Maqbool , Sahrish Rashid , Arslan Shahzad , Sidra Rafique_2019, title={Frequency of side effects of sofosbuvir and daclatsavir in patients of chronic Hepatitis C}, volume={23}, url={http://journalrmc.com/index.php/JRMC/article/view/1150}, abstractNote={<p><strong>Objective</strong>: To evaluate side effects of direct acting antivirals for hepatitis C patients.<br /><strong>Study Design</strong>: Descriptive case series.<br /><strong>Setting</strong>: Hepatitis Clinic, Medical Unit II, Jinnah Hospital Lahore.<br /><strong>Duration Of Study</strong>: three months starting from 1st Dec 2018 to 28th Feb 2019.</p> <p><strong>Subjects And Methods</strong>: Forty patients meeting the inclusion criteria were included in the study. All patients <br />were then given direct anti-virals for a period of three months. Patients were called after every four weeks and <br />observed for the presence of side effects like fever, fatigue, malaise, generalized weakness, myalgia, nausea and <br />vomiting. Data was entered and analyzed in SPSS version ver.21.0. Frequency and percentages were calculated <br />for demographic and clinical profile and side effects. Mean and Standard deviation was calculated for <br />biochemical values at base line and end of therapy. Chi-square test was used to assess side effects among age, <br />gender and duration of disease and paired t test for biochemical parameters with p < .05 as statistical significance.</p> <p><strong>Results:</strong> Mean age of the patients was 39 years + 11.6. Fever was recorded in 72.5% fatigue was seen in 52.5%, <br />malaise was recorded in 37.5% and generalized weakness was noticed in 37.5. Myalgia was recorded in 12.5% and <br />nausea and vomiting were reported in 2.5% of patients. . (p> .05). There was a statistically significant difference <br />between mean baseline and at end treatment values for AST, ALT, AP and TLC. ( P< .05). </p> <p><strong>Conclusion</strong>: Our study concluded that along with efficacy advantage of DAA therapy, their safety profile is <br />acceptable in terms of adverse drug reaction of immediate or during treatment however long term follow up is <br />needed to ascertain and apprehend the safety matters linked with the utilization of DAAs.</p> <p><strong>Key Words</strong>: Direct acting antivirals (DAAs), side effects, chronic hepatitis C.</p>}, number={3}, journal={Journal of Rawalpindi Medical College}, author={ KhawajaTahirMaqbool,SahrishRashid,ArslanShahzad,SidraRafique, KhawajaTahirMaqbool,SahrishRashid,ArslanShahzad,SidraRafique}, year={2019}, month={Sep.} }